Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences?

Learning Objectives After completing this course, the reader will be able to: Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combinati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Jg. 17; H. 12; S. 1534 - 1540
Hauptverfasser:	Kwa, Maryann, Baumgartner, Robert, Shavit, Linda, Barash, Irina, Michael, Jeffrey, Puzanov, Igor, Kopolovic, Juri, Rosengarten, Ora, Blank, Stephanie, Curtin, John P., Gabizon, Alberto, Muggia, Franco
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Durham, NC, USA AlphaMed Press 01.12.2012
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Bevacizumab Chronic kidney disease Creatinine - blood Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Fatal Outcome Female Gynecologic Oncology Humans Middle Aged Ovarian cancer Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Pegylated liposomal doxorubicin Platinum - therapeutic use Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Quality of Life Recurrence Renal Insufficiency, Chronic - etiology Renal Insufficiency, Chronic - pathology Renal thrombotic microangiopathy Retrospective Studies Risk Factors Taxoids - therapeutic use Thrombosis - etiology Thrombosis - pathology Topotecan - administration & dosage Topotecan - adverse effects
ISSN:	1083-7159, 1549-490X, 1549-490X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!